Current Issue Table of Contents: European Journal of Cancer

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Olivier Bylicki,
Pascale Tomasini,
Gervais Radj,
...
Chantal Decroisette,
Laurent Greillier
on behalf of GFPC

Published online: January 29, 2023

p38-48

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study

Jürgen Wolf,
Edward B. Garon,
Harry J.M. Groen,
...
Maria Reynolds,
Bintu Sherif,
Rebecca S. Heist

Published online: January 10, 2023

p98-108

Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors

Fariba Tohidinezhad,
Dennis Bontempi,
Zhen Zhang,
...
Lizza E.L. Hendriks,
Alberto Traverso,
Dirk De Ruysscher

Published online: February 08, 2023

p142-151

Open Access

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Martin Reck,
Tudor-Eliade Ciuleanu,
Manuel Cobo,
...
Steven I. Blum,
John R. Penrod,
David P. Carbone

Published online: January 28, 2023

p174-187

The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial

Karen Bolhuis,
Marinde J.G. Bond,
Martin J. Van Amerongen,
...
Cornelis J.A. Punt,
Rutger-Jan Swijnenburg
for the Dutch Colorectal Cancer Group Liver Expert Panel

Published online: January 30, 2023

p49-59

Open Access

Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma

Isabel Porth,
Daniela Hirsch,
Yonca Ceribas,
...
Ralf-Dieter Hofheinz,
Sylvie Lorenzen,
Timo Gaiser

Published online: February 03, 2023

p119-130

Open Access

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Yungan TAO,
Xu-Shan Sun,
Yoann Pointreau,
...
Kathrin Gollmer,
Heidi Nauwelaerts,
Jean Bourhis

Published online: January 27, 2023

p24-37

Open Access

Characterisation and outcome of RAC1 mutated melanoma

Georg C. Lodde,
Philipp Jansen,
Rudolf Herbst,
...
Dirk Schadendorf,
Selma Ugurel,
Klaus Griewank

Published online: January 17, 2023

p1-10

Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland

Ulrike Keim,
Alexander Katalinic,
Bernd Holleczek,
Marlies Wakkee,
Claus Garbe,
Ulrike Leiter

Published online: January 27, 2023

p60-68

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

Alison M. Weppler,
Laetitia Da Meda,
Ines Pires da Silva,
...
Paolo A. Ascierto,
Celeste Lebbe,
Shahneen Sandhu

Published online: January 28, 2023

p109-118

Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma

Lucas Schneider,
Christoph Wies,
Eva I. Krieghoff-Henning,
...
Jochen S. Utikal,
Dirk Schadendorf,
Titus J. Brinker

Published online: February 03, 2023

p131-138

Open Access

A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl)

Emanuela Palmerini,
Marco Gambarotti,
Antoine Italiano,
...
Toni Ibrahim,
Silvia Stacchiotti,
Bruno Vincenzi

Published online: January 17, 2023

p11-23

Cancers attributable to infectious agents in Italy

Giulia Collatuzzo,
Carlo La Vecchia,
Fabio Parazzini,
...
Claudio Pelucchi,
Eva Negri,
Paolo Boffetta

Published online: January 24, 2023

p69-78

Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial

Marc Hilmi,
Maud Kamal,
Sophie Vacher,
...
Christophe Le Tourneau,
Ivan Bieche,
Cindy Neuzillet

Published online: February 07, 2023

p152-161

The safety risk of information overload and bureaucracy in oncology clinical trial conduct

Stefan G. van Ravensteijn,
Mirte Meijerink,
Renée Nijenhuis-van Schayk,
...
Kalijn F. Bol,
Carla M.L. van Herpen,
Henk M.W. Verheul

Published online: January 27, 2023

p90-94

Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience

Matteo Repetto,
Edoardo Crimini,
Luca Boscolo Bielo,
...
Angela Esposito,
Massimo C.P. Barberis,
Giuseppe Curigliano

Published online: January 30, 2023

p79-89

Far-reaching impact of the Russian invasion of Ukraine on global cancer research

Igor Bondarenko,
Ajay Agarwal,
Mieke Van Hemelrijck,
Mark Lawler,
Mykola Zubaryev,
Richard Sullivan

Published online: February 02, 2023

p95-97

Open Access

Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England

Jennifer Hirst,
Emma Mi,
Emma Copland,
Martina Patone,
Carol Coupland,
Julia Hippisley-Cox

Published online: February 09, 2023

p162-170

Open Access

Refusal of vaccination against influenza and COVID-19 in patients with solid cancers: from bio-ethical issues to solutions

Henri-Corto Stoeklé,
Sakina Sekkate,
Alexandre Vallée,
Philippe Beuzeboc,
Christian Hervé

Published online: February 08, 2023

p139-141

Letter re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France

Bernard Guennebaud,
Alain Rivoire

Published online: February 13, 2023

p171-173

Letter Re: Survival trends in solid cancers in the Nordic countries through 50 years

Siri Larønningen,
Hans H. Storm

Published online: February 14, 2023

p188-189

Response to letter entitled: Re: Survival trends in solid cancers in the Nordic countries through 50 years

Kari Hemminki

Published online: February 13, 2023

p190

April 2023

Lung cancer

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study

Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Gastrointestinal oncology

The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial

Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma

Head and neck oncology

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Melanoma and skin cancers

Characterisation and outcome of RAC1 mutated melanoma

Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma

Sarcoma

A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl)

Epidemiology and prevention

Cancers attributable to infectious agents in Italy

Tumour Immunology and Immunotherapy

Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial

Digital Oncology

The safety risk of information overload and bureaucracy in oncology clinical trial conduct

Other

Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience

Far-reaching impact of the Russian invasion of Ukraine on global cancer research

Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England

Correspondence

Refusal of vaccination against influenza and COVID-19 in patients with solid cancers: from bio-ethical issues to solutions

Letter re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France

Letter Re: Survival trends in solid cancers in the Nordic countries through 50 years

Proper referencing is necessary when using free-of-charge online cancer statistics resources, like NORDCAN

Response to letter entitled: Re: Survival trends in solid cancers in the Nordic countries through 50 years